Streetbeat News

Analyst Ratings

FDX

Deutsche Bank analyst Amit Mehrotra has maintained a 'Buy' rating on FedEx (NYSE:FDX) and raised the price target from $255 to $295.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:20 pm

PEB

Truist Securities analyst Gregory Miller has reiterated a 'Hold' rating on Pebblebrook Hotel (NYSE:PEB) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:19 pm

SPLK

Truist Securities analyst Joel Fishbein maintains a Buy rating on Splunk (NASDAQ:SPLK) and raises the price target from $130 to $157.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:17 pm

TVTX

Evercore ISI Group analyst Liisa Bayko has maintained an 'Outperform' rating on Travere Therapeutics (NASDAQ:TVTX), but lowered the price target from $30 to $14.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:17 pm

BIDU

A significant bullish stance has been taken on Baidu (NASDAQ:BIDU) by a large investor or institution, as indicated by a large position in Baidu's options. The overall sentiment of these big-money traders is split between 73% bullish and 26% bearish. The whales have been targeting a price range from $134.0 to $150.0 for Baidu over the last 3 months. JP Morgan, Susquehanna, Benchmark, and Loop Capital have given price targets of $200, $175, $210, and $190 respectively.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:15 pm

WPC

Evercore ISI Group analyst Steve Sakwa maintains an In-Line rating on W.P. Carey (NYSE:WPC) and lowers the price target from $76 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:15 pm

DRI

Truist Securities analyst Jake Bartlett maintains a 'Buy' rating on Darden Restaurants (NYSE:DRI) and raises the price target from $186 to $190.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:14 pm

ATVI

Wedbush analyst Nick McKay has reiterated an 'Outperform' rating on Activision Blizzard (NASDAQ:ATVI) and maintained a price target of $95.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:11 pm

HRMY

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:09 pm

ALPMF

ALPMY

MRK

SGEN

Seagen Inc and Astellas Pharma Inc released positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck & Co Inc's Keytruda versus chemotherapy in bladder cancer. The trial met its dual primary endpoints of overall survival and progression-free survival compared to chemotherapy. The results are expected to confirm the current U.S. accelerated approval of Keytruda in combination with enfortumab vedotin as first-line treatment for urothelial carcinoma. Seagen's shares are up 3.54% at $213.69.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 3:05 pm